We have located links that may give you full text access.
Core decompression for osteonecrosis of the femoral head in systemic lupus erythematosus.
Clinical Orthopaedics and related Research 1997 January
A cross sectional study was performed to try to identify various demographic and radiologic risk factors for disease progression in 50 patients (79 hips) with corticosteroid associated osteonecrosis of the femoral head who had a core decompression. Thirty-one of the hips were in 18 patients who had systemic lupus erythematosus and were compared with the remaining group of 48 hips in 32 patients who were taking corticosteroids for other reasons. All patients in the study had been taking greater than 30 mg of prednisone for at least 2 weeks at least 6 months before the onset of osteonecrosis. Patients underwent a core decompression and were then observed for an average of 12 years (range, 4-18 years). Overall, 42 of the 79 hips (53%) had satisfactory outcomes. Of the 31 hips in patients with systemic lupus erythematosus, 21 (68%) were converted to a total hip replacement. In the patients without systemic lupus erythematosus taking corticosteroids, 16 of 48 hips (33%) progressed to arthroplasty. A subset of 25 hips from each group (systemic lupus erythematosus and without systemic lupus erythematosus) were matched for age, gender, prednisone dose, Ficat and Arlet Stage, and length of followup. The matched group without systemic lupus erythematosus had 44% survival (11 of 25 hips), which was not statistically different when compared with the 36% survival (9 of 25 hips) found in the systemic lupus erythematosus group. The major risk factors for disease progression were late stage of disease (Stage III) at presentation and radiographic extent of the lesion (>200 degrees), regardless of diagnosis. None of the factors that have been found to be associated with osteonecrosis in patients with systemic lupus erythematosus could be associated with disease progression. Because cause seems to be less significant than the onset and extent of the disease, the clinician should make the diagnosis of osteonecrosis as promptly as possible so that treatment can be started at the earliest possible time, when it will be most efficacious.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app